Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Initial Safety and Preliminary Efficacy of the Novelrad Vascular Closure System (NVCS)

29 de septiembre de 2026 actualizado por: Novelrad Ltd.

A First in Human (FIH) Clinical Study to Evaluate the Initial Safety and Preliminary Efficacy of the Suture-Mediated Novelrad Vascular Closure System

This study evaluates the initial safety and preliminary efficacy of the Novelrad Vascular Closure System (NVCS), a suture-mediated vascular closure system, in achieving post-procedure hemostasis in subjects undergoing interventional catheterization procedures through the common femoral artery using large-bore procedural sheaths.

Descripción general del estudio

Descripción detallada

The Novelrad Vascular Closure System (NVCS) is an investigational suture-mediated vascular closure device intended for use following percutaneous interventional catheterization procedures performed through the common femoral artery using large-bore procedural sheaths. The NVCS is designed to facilitate percutaneous closure of the arteriotomy using a continuous suture technique.

The study is being conducted to evaluate the initial safety and preliminary efficacy of the NVCS in subjects undergoing percutaneous interventional catheterization procedures using large-bore procedural sheaths.

Tipo de estudio

Intervencionista

Inscripción (Actual)

15

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Jerusalem, Israel
        • Hadassah Medical Center
      • Jerusalem, Israel
        • Shaare Zedek Medical Center
      • Tel Aviv, Israel
        • Sourasky Tel-Aviv Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Subject is ≥18 years old.
  2. Subject is scheduled for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter interventional procedures involving access through the femoral artery using 8-22 French introducer sheaths such as TAVI/TAVR/EVAR/TEVAR etc.
  3. Subject has suitable sized vessel / calcification as evaluated on pre-procedural CT angiography by the investigator and by the study' screening committee
  4. Subject is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery
  5. Understand and sign the study specific written informed consent form
  6. Able and willing to fulfill the follow-up requirements

Exclusion Criteria:

Baseline Exclusions:

  1. Known to be pregnant or lactating.
  2. Immunocompromised or with pre-existing autoimmune disease.
  3. Systemic infection or a local infection at or near the access site.
  4. Significant anemia (Hgb < 9 g/dL hematocrit <30%).
  5. Morbidly obese or cachectic (BMI >40 kg/m2 or <20kg/m2).
  6. Known bleeding disorders including thrombocytopenia (platelet count <100,000 cells/UL), thrombasthenia, hemophilia, von Willebrand disease, or hypercoagulability.
  7. Known allergy to any device component.
  8. Femoral artery puncture in target groin within the prior 14 days, recent femoral artery puncture in target groin that has not healed appropriately, and/or prior vascular closure device placement in target common femoral artery that the investigator determines may interfere with the NVCS.
  9. Common femoral artery with calcium, as determined by baseline CTA, precluding safe access in the opinion of the investigator or severe peripheral vascular disease as evidenced by severe claudication when ambulating < 30 meter, weak or absent pulses in the affected limb.
  10. Previous intervention in region of access site, including but not limited to prior atherectomy, stenting, surgical or grafting procedures in the access area.
  11. Prior target artery closure with any closure device < 180 days, or closure with manual compression ≤ 90 days prior to index procedure.
  12. Subjects who have undergone use of an intra-aortic balloon pump through the arterial access site.
  13. Undergoing therapeutic thrombolysis.
  14. Subjects in whom oral anticoagulation therapy cannot be stopped for the peri-procedural period or subjects with INR >1.8 at the time of the procedure.
  15. Subject unable to be adequately anti-coagulated for the procedure.
  16. Subjects who are not mobile and are confined to a wheelchair or bed.
  17. ST-elevation MI within 45 days prior to procedure or acute coronary syndrome (i.e., unstable angina or myocardial infarction) ≤14 days before the catheterization procedure
  18. NYHA class IV heart failure.
  19. Left ventricular ejection fraction <20%.
  20. Unilateral or bilateral lower extremity amputation.
  21. Renal insufficiency (serum creatinine >2.5 mg/dl) or on dialysis therapy, or after renal transplant.
  22. Existing nerve damage in the NVCS treated leg.
  23. Further planned endovascular procedure within the next 30 days.
  24. Subjects currently participating in another clinical study of an unapproved investigational device or drug that has not concluded the follow-up period.
  25. Subject cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence, psychiatric condition or life-threatening disease.
  26. Common femoral artery <6mm or >50% diameter femoral stenosis by baseline CTA and/or severe peripheral arterial disease or Rutherford Classification 5 or 6.
  27. Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
  28. Known severe allergy to contrast reagent that cannot be managed with premedication.
  29. Connective tissue disease (e.g., Marfan's Syndrome).
  30. Thrombolytics (e.g., streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants ≤ 24 hours prior to the procedure.
  31. Subject is mentally incompetent or a prisoner.
  32. Planned antegrade puncture during the index procedure.
  33. Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.
  34. Subject unable to ambulate at baseline (i.e., confined to wheelchair or bed).

Intra-Procedure Exclusions:

  1. On baseline Duplex US the Common femoral artery <6mm or >50% stenosis of the femoral artery.
  2. Puncture site took place in the profunda femoris artery, superficial femoral artery, or at the bifurcation of these arteries or if less than one third of the access needle is above the skin line indicating the subject is morbidly obese.
  3. Common femoral artery suspected to have experienced a back wall puncture or underwent > one (1) arterial puncture during the catheterization procedure.
  4. Difficult dilation from initial femoral artery access (e.g., damaging or kinking dilators) while step dilating up to the large-bore device.
  5. Actual puncture site located above the most inferior border of the epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks.
  6. Marked tortuosity of femoral or iliac artery that to the opinion of the user prohibiting the use of the device.
  7. Systolic blood pressure >180 mmHg or diastolic blood pressure >110 mm Hg, unless systolic or diastolic pressure can be lowered by pharmacological agents prior to closure.
  8. Planned antegrade puncture during the index procedure.
  9. Possible bacterial contamination of the procedure's sheath or surrounding tissues during the procedure.
  10. Intra-procedural complication(s) at the femoral access site before procedural sheath removal and before sliding the NVCS knot down, including: 1. Bleeding or swelling around the sheath that may indicate hematoma formation and/or pseudoaneurysm formation; and 2. Peri-procedural duplex us/angiographic evidence of thrombus formation or significant injury in the aorta or iliac vessels associated with procedural large bore sheath placement and/or sub-optimal anticoagulation.
  11. Presence of ipsilateral femoral venous sheath during the interventional procedure.
  12. Systolic blood pressure <90 mm Hg just prior to planned vascular closure without the ability to increase it.
  13. Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
  14. Index procedure planned sheath or interventional device >22Fr during the procedure.
  15. Evidence of a pre-existing hematoma (> 1.5 cm in diameter), arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the access site before insertion of the NVCS.
  16. Duplex US (or by angiography if applicable) evidence of arterial laceration, dissection, or stenosis in the femoral artery that would preclude use of the device.
  17. Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Novelrad Vascular Closure System (NVCS)

The Novelrad Vascular Closure System (NVCS), will be used in subjects who are undergoing diagnostic or interventional catheterization procedures

NVCS will be used to close the common femoral artery access site while reducing time-to-hemostasis in subjects who have undergone diagnostic or interventional catheterization procedures using 8-22 French (F) Sheaths.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety: Freedom from major complications of the target limb within 30 days following the procedure
Periodo de tiempo: Within 30 days post-procedure

Assessment of the incidence of protocol defined major complications of the target limb access site through 30 days post procedure as specified in the protocol.

Within 30 days post-procedure
Efficacy: Mean Time to Hemostasis
Periodo de tiempo: Periprocedural

The Time to Hemostasis is defined as the elapsed time between withdrawal of index procedure sheath from common femoral artery and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).

Periprocedural

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety: Frequency of minor complications at the target limb.
Periodo de tiempo: Within 30 days post procedure

Assessment of the incidence of minor complications of the target limb access site as specified in the protocol.

Within 30 days post procedure
Efficacy: Technical Success
Periodo de tiempo: Periprocedural

Achievement of hemostasis with the NVCS without the need for any access-site-related adjunctive surgical or endovascular intervention (target limb only).

Periprocedural
Efficacy: Treatment/Procedure Success
Periodo de tiempo: Within 30 days post procedure

Subjects with technical success and free from major complications through 30 days follow-up.

Within 30 days post procedure
Efficacy: Mean Time for NVCS Procedure
Periodo de tiempo: Periprocedural

The elapsed time from initial skin break (first needle insertion) to time when the suture is released from the NVCD plus the elapsed time from performing the knot at the end of the index procedure and until hemostasis is achieved.

Periprocedural
Efficacy: Mean Time to Ambulation
Periodo de tiempo: Within 24 hours after procedural sheath removal

The elapsed time between last procedural sheath removal and when ambulation is achieved (subject is standing and walking at least 6-meters without bleeding).

Within 24 hours after procedural sheath removal
Time-to-discharge eligibility
Periodo de tiempo: Within 48 hours after the procedure

The time following the removal of the NVCS and when the patient is eligible for discharge based solely on (1) completion TTA, (2) freedom from orthostatic hypotension [defined as stable blood pressure and heart rate after ambulating], (3) ability to void and, (4) a stable access site without bleeding or expansion of a prior hematoma.

Within 48 hours after the procedure
Efficacy: Percent of subjects with surgical or endovascular intervention post closure
Periodo de tiempo: Periprocedural

Subjects require adjunctive surgical or endovascular intervention to achieve hemostasis of the NVCS access site.

Periprocedural
Efficacy: Percent of subjects with NVCS Failure
Periodo de tiempo: Periprocedural

When the device is used in accordance with the IFU, but does not perform as described in the IFU, and/or negatively impacts treatment of the study subject.

Periprocedural

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Yossi Muncher, Ph.D., Novelrad Ltd.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

30 de noviembre de 2025

Finalización primaria (Actual)

18 de agosto de 2026

Finalización del estudio (Actual)

18 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

17 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Publicado por primera vez (Actual)

5 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NVCS-CLN-001

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir